GlassScriptPhysician profile
John D Jeppson
NPI 1417943622
$64,928.89
in general payments reported to CMS, 2019-2025
33 companies · $382 in 2025
The $382 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $2,168 · 2021: $6,986 · 2022: $21K · 2023: $16K · 2024: $2,423 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $2,882 · Travel and Lodging: $1,206 · Consulting Fee: $36.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,575.00 |
| Food and Beverage | $2,881.86 |
| Travel and Lodging | $1,206.16 |
| Consulting Fee | $36.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $59,337.12 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Octapharma USA, INC. | $812.00 | 2019-2023 | Cutaquig |
| Glaxosmithkline, LLC. | $607.59 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $607.53 | 2019-2025 | |
| Blueprint Medicines Corporation | $466.54 | 2023-2025 | Ayvakit |
| Grifols USA, LLC | $435.59 | 2019-2024 | Prolastin-C Liquid, Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $383.79 | 2020-2024 | Glassia, Hyqvia |
| Csl Behring | $354.88 | 2019-2024 | Hizentra |
| Regeneron Healthcare Solutions, INC. | $334.06 | 2019-2024 | Dupixent |
| Amgen INC. | $237.68 | 2020-2024 | Tezspire |
| Pharming Healthcare, INC. | $177.01 | 2020-2023 | Joenja |
| Biocryst US Sales Co., LLC | $153.68 | 2022-2024 | Orladeyo |
| Genentech USA, INC. | $133.68 | 2022-2024 | Xolair |
| Pfizer INC. | $116.82 | 2020-2024 | |
| Mylan Specialty L.P. | $90.23 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $87.89 | 2021-2022 | |
| Adma Biomanufacturing LLC | $78.94 | 2022-2023 | |
| Sanofi US Services INC. | $66.86 | 2025 | |
| Aimmune Therapeutics, INC. | $65.94 | 2020-2022 | |
| Leo Pharma INC. | $61.15 | 2022 | |
| Novartis Pharmaceuticals Corporation | $55.24 | 2020-2023 | |
| Abbvie INC. | $43.55 | 2022 | |
| Bio Products Laboratory USA, INC. | $28.83 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.32 | 2019-2021 | |
| Incyte Corporation | $26.71 | 2023 | Opzelura |
| Biocryst Pharmaceuticals, INC. | $23.16 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.22 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.11 | 2021 | |
| Shire North American Group INC | $18.95 | 2019 | |
| Merck Sharp & Dohme LLC | $16.87 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.24 | 2019 | |
| Horizon Therapeutics Plc | $12.97 | 2021 | |
| Lundbeck LLC | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Jeppson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.